Your SlideShare is downloading. ×
0
Q1 2013 Investor Conference Call Presentation Charts
Q1 2013 Investor Conference Call Presentation Charts
Q1 2013 Investor Conference Call Presentation Charts
Q1 2013 Investor Conference Call Presentation Charts
Q1 2013 Investor Conference Call Presentation Charts
Q1 2013 Investor Conference Call Presentation Charts
Q1 2013 Investor Conference Call Presentation Charts
Q1 2013 Investor Conference Call Presentation Charts
Q1 2013 Investor Conference Call Presentation Charts
Q1 2013 Investor Conference Call Presentation Charts
Q1 2013 Investor Conference Call Presentation Charts
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Q1 2013 Investor Conference Call Presentation Charts

402

Published on

Q1 2013 Investor Conference Call Presentation Charts

Q1 2013 Investor Conference Call Presentation Charts

Published in: Investor Relations
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
402
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Q1 2013 Results Investor Conference Call April 25, 2013 / Marijn Dekkers, CEO
  • 2. Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. • Q1 2013 Investor Conference Call • Marijn DekkersPage 2
  • 3. Page 3 Q1 2013 – LifeScience Businesses Off To A Good Start  HealthCare benefits from successful launch of new products and strong growth in Consumer Care  CropScience continues to grow profitably in ongoing favorable market environment  Cost pressure at MaterialScience resulted in earnings performance below expectations  Group sales organically +4%; reported EBIT +9%; adjusted* EBITDA at prior-year level  Full-year 2013 Group outlook confirmed • Q1 2013 Investor Conference Call • Marijn Dekkers *before special items
  • 4. Page 4 EBIT in € million +9% 1,771 1,631 Sales in € million % currency & portfolio adj. +4% 10,266 10,054 EBITDA adjusted** in € million 0% 2,4532,443 Core EPS in € +2% 1.701.67 *Prior-year figures restated. **before special items Q1’13Q1’12* Q1’13Q1’12* Q1’13Q1’12* Q1’13Q1’12* Q1 2013 – Total Group: LifeSciences Commence Positively • Q1 2013 Investor Conference Call • Marijn Dekkers
  • 5. Regional Performance - Growth Led By USA And Emerging Economies Page 5 Africa & Middle East Eastern Europe Emerging Economies Emerging Economies¹ +7% Others² +8% USA +8% Western Europe -3% Q1 2013 Group Sales by Region Group €10,266m; +4% ~1,000 +8% ~1,400 +8% ~400 -7%~700 +13% ¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe ² Others = Japan, Australia, New Zealand, Canada ³ Emerging Asia = Asia w/o Japan, Australia, New Zealand In € million, ∆% yoy Fx adjusted 34% 12%32% 22% Latin America Emerging Asia³ • Q1 2013 Investor Conference Call • Marijn Dekkers
  • 6. Q1 2013 – Cash Flow And Net Debt Development Page 6 +€491m 7.5 GCF oFCF 1,807 Invest- ments 365 (38) ∆ y-o-y +13% -100% NCF 327 +38% +43% Dec 31, 2012 Mar 31, 2013 7.0 Q1 2013 Cash Flow Net Debt Development Cash Flow in € million, Net Debt in € billion • Q1 2013 Investor Conference Call • Marijn Dekkers
  • 7. Q1 2013 – HealthCare: New Products and Consumer Care Drive Growth Page 7 *before special items Q1 2013 Sales Earnings1 Pharma +2% (+5%) Consumer Health +3% (+5%) 36% HealthCare €4,443m; +2% (+5%) 2,5641,879 Price +1% Volume +4% Fx -3% Portfolio 0% In € million, ∆% yoy, () = Fx & portf. adjusted Q1‘12 Q1‘13 Q1‘12 Q1‘13 740 832 441 445 +12% +1% 1,181 1,277 +8% 341 +1% 861 953 +11% 520 343 Adj. EBITDA* Adj. EBIT* 610 +17% • Q1 2013 Investor Conference Call • Marijn Dekkers 1 Prior-year figures restated.
  • 8. Q1 2013 – CropScience: ContinuouslyStrong In Favorable Market Environment Page 8 Crop Protection +9% (+11%) Environmental Science -12% (-10%) Seeds +1% (0%) Q1 2013 Sales Earnings1 In € million, ∆% yoy, () = Fx & portf. adjusted CropScience €2,764m; +6% (+7%) Price +3% Volume +4% Fx -2% Portfolio 0% 2,111 Q1‘12 Q1‘13 Q1‘12 Q1‘13 984 1,081 +10% 864 969 +12% Adj. EBITDA* Adj. EBIT* 164 489 • Q1 2013 Investor Conference Call • Marijn Dekkers *before special items 1 Prior-year figures restated.
  • 9. Q1 2013 – MaterialScience: Cost Pressure Prevented A Better Performance Page 9 **CAS: Coatings, Adhesives, Specialties *** IO: Industrial Operations Polyurethanes +3% (+4%) Polycarbonates -6% (-6%) CAS** -3% (-3%) Q1 2013 Sales Earnings1 In € million, ∆% yoy, () = Fx & portf. adjusted *before special items MaterialScience €2,775m; +0% (+0%) Price +4% Volume -4% Fx -1% Portfolio 0% 1,469 663 IO*** +0% (+1%) Q1‘12 Q1‘13 Q1‘12 Q1‘13 Adj. EBITDA* Adj. EBIT* 279 204 -27% 121 43 -65% 467 176 • Q1 2013 Investor Conference Call • Marijn Dekkers 1 Prior-year figures restated.
  • 10. FY 2013 Group Outlook Confirmed Page 10 20121 ∆ vs. 2011 2013E Sales €39.7bn +5% +4-5% to ~€41bn* adj. EBITDA €8.3bn +9% mid-single-digit % increase Core EPS €5.30 +10% high-single-digit % increase Sales ∆ Fx and portfolio adjusted, EBITDA before special items *Assuming Fx rate of $1.29 per € Outlook depends on specific planning assumptions as detailed in the Annual Report• Q1 2013 Investor Conference Call • Marijn Dekkers 1 2012 figures restated.
  • 11. Q1 2013 Results Investor Conference Call April 25, 2013 / Marijn Dekkers, CEO

×